Publications by authors named "Elefteri M Buset"
Article Synopsis
- The study assessed the effects of pegfilgrastim versus filgrastim on patient outcomes after high-dose BEAM therapy and autologous stem cell transplant in lymphoma patients.
- Analysis included 54 patients, with no significant differences found in neutropenia, thrombocytopenia, fever duration, or hospital stay between the two treatment groups.
- Although pegfilgrastim led to a 12% increase in treatment costs, it was deemed comparable to filgrastim for managing lymphoma post-transplant.
To reduce the duration of neutropenia after conditioning chemotherapy and autologous peripheral blood stem cell transplantation (APBSCT), granulocyte-colony stimulating factors (G-CSF) are commonly administered. We retrospectively evaluated the impact of pegfilgrastim compared to filgrastim on neutrophil engraftment, hospital stay, and supportive measures in patients with multiple myeloma after conditioning with Melphalan 200 (Mel200) followed by APBSCT. Ninety-two APBSCT after Mel200 treatment were performed in 72 patients between January 2006 and December 2009 at our institution.
View Article and Find Full Text PDF